Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of Leramistat in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of Leramistat in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leramistat (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Sponsors Istesso

    • Most Recent Events

    • 09 Apr 2025 Status changed from recruiting to withdrawn prior to enrolment (Reason the study was stopped: Due to slow initial recruitment and a lack of confidence in our ability to complete recruitment within the forecasted timeframe.)
    • 06 Sep 2023 Status changed from not yet recruiting to recruiting.
    • 10 Aug 2023 Planned initiation date changed from 1 Jul 2023 to 1 Aug 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top